Anti-TFAM antibodies are detected in about one third of patients with systemic lupus erythematosus and are associated with a ...

Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically ...

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

A new study identifies eight domains of active systemic #lupus erythematosus for defining meaningful treatment response in ...

An AI-driven, 3D spatial multimodal analysis exposed substantial immune and structural dysregulation of the duodenum in ...

New study finds that elevated S100A8/A9 levels in blood may be associated with cognitive impairment in adults with #lupus.

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.

Vaccines and ongoing vigilance are critical to prevent and manage infections in patients who are immunosuppressed or ...

Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is anticipated to provide QRX003 with the broadest possible label ...

A new study presented at COMy 2025 reveals that patients with amyloid light-chain amyloidosis still face significant delays ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may ...